antigen-experienced T cells to and from bone marrow, lymphoid organs and peripheral tissues under homeostatic and inflammatory conditions 4 (Fig. 1) .
Chimen et al. 1 found that treatment with an S1PR1 antagonist made T cells unresponsive to the effects of PEPITEM or adiponectin, whereas addition of exogenous S1P at levels found in blood blocked T cell TEM. Further, upon stimulation by PEPITEM, cadherin-15 induced S1P biosynthesis via sphingosine kinase 1, which was upregulated in response to tumor necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ). Either chemical inhibition of sphingosine kinase or knockdown of the S1P transporter Spns2 blocked PEPITEM's effect on T cell transmigration.
Blood S1P levels are constitutively high, and S1PR1 is desensitized and internalized in T cells under these conditions. How, then, does a minor change in local S1P levels create a recognizable signal, and how can adherent T cells bathed in blood sense the gradient if they lack S1PR1 expression? The authors rationalized that most circulating S1P is protein-bound and inactive; adherent T cells could, therefore, potentially detect a pulse of free S1P at the endothelial cell apical surface 1, 5 . Interestingly, this suggests that effective 'S1P gradients' may act on a microenvironmental scale. Second, the authors demonstrated that memory T cells upregulate surface S1PR1 expression (sustained even in the presence of high S1P concentrations) under inflammation-like conditions 1 .
T cell TEM requires strong interactions between the integrin receptor LFA-1 and endothelial intercellular adhesion molecule 1 (ICAM-1). Interestingly, S1P signaling reduced the affinity of LFA-1 for ICAM-1 under inflammatory conditions, which appears to be the fundamental mechanism by which S1P halts Autoimmune disease represents a group of over 100 medical conditions, some with high prevalence and on the rise worldwide, in which the immune system fails to distinguish self from non-self, resulting in immunemediated tissue damage. The healthy immune system fine-tunes responses through myriad mechanisms, including regulation of lymphocyte trafficking to sites of inflammation. In this issue of Nature Medicine, Chimen et al. 1 reveal a previously unknown activity of B cells that prevents memory T cells from undergoing transendothelial migration (TEM) from blood into inflamed tissues (Fig. 1) . This effect presumably tempers the inflammatory cascade by reducing the release of T cell-derived cytokines and further immune cell recruitment. In individuals with autoimmune diseases, however, the process malfunctions.
The authors made their discovery while investigating adiponectin's effect on lymphocyte migration 1 . Adiponectin is an adipokine involved in metabolism, adipogenesis and diabetes. Recently, adiponectin and its receptors AdipoR1 and AdipoR2 were shown to inhibit leukocyte recruitment to inflamed endothelium 2 . Furthermore, low levels of circulating adiponectin have been observed in some diseases, including diabetes 3 . To explore adiponectin's influence on lymphocyte TEM in detail, the authors carried out in vitro transmigration assays, isolating peripheral blood lymphocytes (PBLs) from healthy individuals and following their movement across confluent monolayers of TNF-α-and IFN-γ-stimulated endothelial cells by video-microscopy.
They found that adiponectin inhibited cytokine-induced transmigration of memory T cells across the endothelium without influencing T cell recruitment 1 . Although the authors considered a direct effect on T cells to be the most plausible explanation for their observations, this possibility was ruled out 1 . Further investigation revealed that adiponectin's effect was mediated through B cells, which (unlike T cells) expressed high AdipoR levels. Depleting B cells from PBL mixtures released the adiponectin-induced blockade on migration, whereas adding back B cells or conditioned medium from adiponectin-treated B cells restored the blockade.
Using proteomics, the authors identified a peptide released from B-cells after adiponectin stimulation, which they named PEPITEM for PEPtide Inhibitor of Trans-Endothelial Migration 1 (Fig. 1) . Described for the first time in this study, PEPITEM is a small peptide derived from the 14.3.3.ζδ protein by proteolytic cleavage. A biotin-conjugated PEPITEM was used to identify its unknown receptor, endothelial cell cadherin-15, an adhesion protein expressed in myoblasts but not previously recognized as part of the endothelial cell expressed gene repertoire.
When searching for a mechanism by which PEPITEM influenced T-cell TEM, the authors focused on sphingosine-1-phosphate (S1P), a bioactive sphingolipid known to orchestrate T cell trafficking 1 . S1P controls T cell migration through S1P receptors (S1PRs) which respond to S1P gradients between tissues where S1P levels are low, and blood and lymph, where they are high 4 . By signaling through S1PR1, S1P regulates T cell trafficking, influencing the entry, retention and egress of naive and n e w s a n d v i e w s nature medicine volume 21 | number 5 | mAY 2015adiponectin-induced PEPITEM released by B cells. PEPITEM treatment, however, could reduce TEM of the patients' T cells. Patients with T1D also had lower plasma PEPITEM levels than controls 1 . In the elderly, a population at risk for autoimmune diseases, the process was also compromised, as their B cells exhibited reduced AdipoR expression compared to younger individuals. Altogether, these results suggest this immunoregulatory mechanism is compromised in autoimmunity and aging.
The 'adiponectin-PEPITEM axis' expands an ever-growing list of mechanisms by which B cells modulate immune responses independently of antibody production 7 . Effector B cells amplify humoral and cellular immunity through pro-inflammatory cytokine production. Conversely, regulatory B cells restrain immune responses through transforming growth factor beta 1 (TGF-β1) and interleukin 10 (IL-10) secretion, suppression of T helper 1 (T H 1)-, T H 17-and T H 2-mediated responses, and the induction and maintenance of regulatory T cells 8 . In contrast to regulatory B cells, plasma cells have not yet been recognized to have immunosuppressive functions. However, these authors now show that PEPITEM, which has immunosuppressive actions, is derived primarily from plasma cells, which contradicts the ascribed role of these cells as culprits in autoimmunity and reveals them as 'double agents' in immune regulation.
T cell entry into inflamed tissues ( Fig. 1)  (ref. 1) . S1P's influence on the interactions between LFA-1 and ICAM-1 is implicated in other aspects of T-cell trafficking, including T cell migration from peripheral tissues into afferent lymphatics 6 . Thus, this could represent a central mechanism by which S1P signaling regulates T cell migration.
A strength of the study is the inclusion of convincing evidence demonstrating the PEPITEM-induced T cell blockade is an endogenous phenomenon. By using a zymosaninduced peritonitis model, the authors showed that mice lacking B cells exhibited greater T cell trafficking into inflamed peritoneal cavities compared to controls, whereas delivery of PEPITEM to the former reduced T cell trafficking 1 . PEPITEM administration also impeded mouse T cell trafficking to infectious foci in a Salmonella model of bacteremia, to hepatic sinusoids after ischemia and reperfusion injury, to ocular infiltrates in endotoxin-induced autoimmune uveitis, and to salivary glands in a virally induced model of Sjogren's syndrome. In contrast, PEPITEM had no impact on B cell recruitment.
Notably, B cells isolated from patients with type I diabetes (T1D) and rheumatoid arthritis had lower AdipoR expression than controls, and their T cell TEM was not inhibited by adiponectin 1 . In both T1D-affected individuals and controls, AdipoR expression levels correlated with the amount of In addition, the role of S1P interactions with S1PR1 in vascular development and integrity are well described 9 . What impact might PEPITEM have on vascular permeability during homeostasis, inflammation, infection and shock? S1PR1 antagonists are known to induce vascular leak 10 . Conversely, what effects do S1PR modulators and B cell depletion strategies currently used to treat disease have on T cell TEM, as revealed by this study? Although in the present study adiponectin's influence on S1P signaling is mediated through a paracrine effect, in other systems AdipoR activation promoted ceramide degradation and S1P synthesis in a cell-autonomous manner via ceramidase activation, suggesting Figure 1 The role of B cells in S1P-mediated regulation of T cell trafficking. (a) In non-inflamed tissues, high S1P concentration in blood results in S1PR1 downregulation on circulating T cells, and interactions between T cell LFA-1 and endothelial cell (EC) ICAM-1 facilitate T cell TEM into non-inflamed tissues. S1P activation of endothelial cell S1PR1 promotes endothelial cell tight junctions, maintaining vascular integrity. (b) Chimen et al. 1 show that in inflamed tissues, adiponectin stimulates B cells through AdipoRs, inducing them to release PEPITEM. PEPITEM binds to its receptor, cadherin-15, on endothelial cells. Cadherin-15 activation leads to production of S1P by the enzyme sphingosine kinase 1 (sphk1). S1P is exported to the extracellular space through the Spns2 transporter. Adherent T cells stimulated by inflammatory signals upregulate S1PR1, which allows them to bind the S1P released locally from endothelial cells. As a result of S1P signaling, T cell LFA-1 and endothelial cell ICAM-1 interactions are reduced; T endothelial cell TEM is blocked, and inflammation is restrained. npg n e w s a n d v i e w s in a dense stroma, which serves as a barrier against therapeutic agents and also induces cellular processes that defend against a wide range of therapies, including OVs. The first line of defense against OV infection is provided by intracellular innate antiviral signals such as type I interferon and extracellular humoral (cytokines, chemokines) and cellular (macrophages, neutrophils, NK cells, T cells, and interferon-producing cells) responses [9] [10] [11] . Therefore, cellular components of the tumor stroma could be useful therapeutic targets to improve OV therapy 12 .
Ilkow et al. 4 first analyzed CAFs and normal fibroblasts from two lung cancer patients and showed that CAFs exhibited more pronounced susceptibility to infection when exposed to a panel of three different OVs. Analyses of the transcriptome of CAFs and normal fibroblasts revealed a reduction in expression of transcripts related to innate antiviral and type I interferon signaling in CAFS compared with normal fibroblasts, a finding that might explain their observed permissiveness to OVs 4 . Interestingly, infection of CAFs by OVs did upregulate these antiviral signaling networks in CAFs to some extent, but it seems that the rate of OV infection and replication was able to outpace this response. The second important observation was that co-cultures of primary human renal cancer cells with CAFs also showed increased infection of both the renal cancer cells and CAFs when compared to infection of either cell alone and this was in this issue of Nature Medicine. They show that cancer-associated fibroblasts (CAFs) are more permissive to OV infection when compared with normal fibroblasts, and that this is due to the presence of signaling cross-talk between CAFs and tumor cells 4 (Fig. 1) . This is mediated by tumor-secreted TGF-β and CAFsecreted FGF2: the latter ultimately reduces innate baseline antiviral defense mechanisms in tumor cells. This finding thus illustrates how the tumor microenvironment can be a key factor in determining the efficacy of cancer virotherapy.
A solid neoplastic mass is a heterogeneous microenvironment, composed not only of tumor cells at different stages of development, but also of a stroma consisting of cells such as tumor-associated endothelial cells and pericytes, as well as tumor-associated immune effector cells such as macrophages, NK cells, T cells and CAFs. These all produce soluble factors that contribute to tumor-associated functions. The ability of a tumor to reprogram these cells in a manner that benefits the tumor remains poorly understood 5 , but the phenotypic transition from normal fibroblast to CAF was shown 4 to be an epigenetically regulated phenomenon that occurs upon fibroblast exposure to tumor-secreted factors such as TGF-β 6 . Fibroblasts are particularly important, as they coordinate crucial interactions between the various stromal and tumor cells to provide an environment conducive to tumor progression 7, 8 . Neoplastic cells flourish Oncolytic viruses (OVs) are a promising biological therapy for the treatment of cancer 1 . Recent advances in genetic engineering have facilitated generation of OVs that can exploit each cancer's unique set of mutations to result in anti-neoplastic activity. Furthermore, the efficacy of oncolytic viruses can be further enhanced with additional therapeutic genes, such as genes that activate prodrugs ('suicide' genes) or immune-stimulatory genes (such as those encoding the cytokines IL-12 or GM-CSF). The virus can unload this 'therapeutic cargo' at the tumor site, thereby enhancing the viral anti-neoplastic properties.
Central to cancer resistance to OVs is the capacity of the neoplasm to mount an anti-viral defense. During viral progeny particle release, tumor host cells are destroyed and tumorassociated antigens are released and recognized by immune cells, leading to immune activation. The virus thus leads to cancer destruction by various mechanisms, including this induction of an anti-tumor immune response and direct oncolysis. However, this has not been shown to occur consistently and reliably in humans in various tumor types 2, 3 . One explanation for this may come from a study by Ilkow et al. 4 that these two important pathways link in multiple ways 11 . S1P-targeted therapies are effective for multiple sclerosis and are being tested in other autoimmune diseases 12 . The potential of harnessing the adiponectin-PEPITEM axis for similar therapeutic purposes is tantalizing. Identifying other disease contexts (atherosclerosis, cancer, trauma, infection, shock, transplantation, graft-versus-host disease) in which this pathway or its dysfunction plays a role, and defining which axis components are affected will be key. The fact that cadherin-15 is expressed at low levels on normal endothelium but upregulated on inflammatory endothelial cells may confer specificity to PEPITEM or agents that could be developed to target this pathway including cadherin-15-specific antibodies or chimeric antigen receptor T cells. The authors' discovery of the adiponectin-PEPITEM pathway and its dysfunction in autoimmune diseases thus offers a novel strategy for potentially restoring immune homeostasis in autoimmunity and other inflammatory conditions.
